Key Development American Industrial Partners has completed its acquisition of Avanos Medical in a transaction valued at approximately US$1.27 billion.... Read more
Tag: #M&A
RIVERPOINT MEDICAL ACQUISITION MOVES NOVANTA DEEPER INTO THE SURGICAL CONSUMABLES MARKET
Key Development Novanta has completed its acquisition of Riverpoint Medical from Arlington Capital Partners, marking a significant expansion of its... Read more
ELI LILLY’S $3.8 BILLION ATAIBECKLEY ACQUISITION SIGNALS BIG PHARMA’S NEXT BET ON NEUROSCIENCE
Key Development Eli Lilly's agreement to acquire AtaiBeckley for up to US$3.8 billion represents more than another biotechnology acquisition it... Read more
IS MEDTECH BECOMING HEALTHCARE’S NEXT M&A HOTSPOT? CONMED WEIGHS STRATEGIC OPTIONS AMID TAKEOVER INTEREST
Takeover speculation lifts investor confidence Shares of medical technology company CONMED Corporation surged in after-hours trading after Bloomberg reported that... Read more
WHY WOULD INVESTORS PAY MORE THAN $7 BILLION FOR A SPECIALTY PHARMACY?
Private equity firm Warburg Pincus is reportedly nearing an agreement to acquire PANTHERx Rare in a transaction valued at more... Read more
WHY THE MERGER OF BAC TAN UYEN REGIONAL MEDICAL CENTER COULD SIGNAL A NEW DIRECTION FOR VIETNAM’S PUBLIC HEALTHCARE SYSTEM
Not every healthcare reform begins with the construction of a new hospital. Sometimes, it begins with a decision to reorganize... Read more
Post-Pandemic Restructuring: BioNTech Executes Confidential Divestment Talks Over 4 German Manufacturing Sites to Fund Oncology Pivot
Key Development German biotechnology pioneer BioNTech SE—the co-developer of the blockbuster Comirnaty mRNA COVID-19 vaccine—has initiated highly confidential discussions with... Read more
Blockbuster ADC Consolidation: Novartis Deploys $1.5 Billion to Acquire Myricx Bio, Securing Next-Gen Payload Platforms to Overcome Tumor Resistance
Key Development Swiss pharmaceutical major Novartis has formally entered into a definitive agreement to acquire U.S./U.K.-based biotechnology innovator Myricx Bio... Read more
Institutional Capital Hedging via Royalty Consolidation: Analyzing Zymeworks’ $929 Million Takeover of Theravance
Key Development Global oncology therapeutics specialist Zymeworks (Vancouver, Canada) has entered into a definitive merger agreement to acquire the distressed... Read more









